Black Diamond Therapeutics Q2 2022 net loss $22.9M; cash $160.9M, runway into Q3 2024

Black Diamond Therapeutics, Inc.

2022-Q2 EPS reported -$1.33

Net loss of $22.9M in Q2 2022, narrowing from $34.4M in Q2 2021.
Cash and investments $160.9M as of June 30, 2022; expected to fund ops into Q3 2024.
First patient dosed in Phase 1 study of BDTX-1535; clinical update expected in 2023.
Appointed Sergey Yurasov as Chief Medical Officer in June 2022.
IND submission for BDTX-4933 targeted for H1 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.